Some with Alzheimer's better off staying on antipsychotics, study reports
October 18, 2012 by Denise Mann, Healthday Reporter in Alzheimer's disease & dementia
Agitation, aggression more likely to return in those who stopped taking Risperdal, research shows.
(HealthDay)—People with Alzheimer's disease who take the antipsychotic drug risperidone (Risperdal) to help curb their agitation and aggression may see a return of these troublesome symptoms if they stop taking the medication, a new study suggests.
Not every person with Alzheimer's will become agitated and/or aggressive, but among those who do, these symptoms make it difficult for caregivers to manage them at home and often lead to nursing home admission and an increased risk of dying from the disease.
As it stands, these antipsychotic drugs are only supposed to be taken for three to six months due to concerns about side effects including weight gain, tremors and movement difficulty. In recent years, the U.S. Food and Drug Administration also placed a black-box warning on this class of medications warning that people with dementia who take antipsychotics have a higher risk of dying.
"Caregivers should be aware of the increased mortality associated with these medications in people with dementia," said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. However, he added, "if a patient is taking an antipsychotic and doing reasonably well without any major side effects, they should stay on it."
The new study, which appears in the Oct. 18 issue of the New England Journal of Medicine, sought to determine what happens when the medication is stopped among people who are doing well on it. The U.S. National Institutes of Health sponsored the trial.
Nursing home staff are tasked with providing written explanations if they choose to keep someone on one of these medications for longer than three to six months, Devanand noted. "One must be cautious about discontinuing the medication. If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely," he said.
Stopping treatment resulted in a relapse of symptoms for those who had been doing well on the medication for four to eight months, the investigators found.
The new study included 180 patients with Alzheimer's disease who showed signs of agitation and aggression. The patients, from eight U.S. centers, all received risperidone for 16 weeks in the first phase of the study. After that, the 110 patients who did well on the drug were assigned to take either risperidone or an inactive placebo. Those who were switched to a placebo were twice as likely to relapse when compared to participants who continued taking risperidone, the study found. What's more, the rate of side effects and death did not differ among participants.
Dr. Gary Kennedy, director of the division of geriatric psychiatry at Montefiore Medical Center in New York City, said that deciding how long to keep a person with Alzheimer's on an antipsychotic drug isn't an easy decision to make.
But "if a person is responding to the drug, it makes sense to stick with it," said Kennedy, who was not involved with the study.
Treating agitation and aggression in someone with Alzheimer's can make a big difference for the patient and the caregiver, he added. "These patients can be dangerous and very difficult to care for," Kennedy noted. "This is a very important study."
More information: Learn more about agitation among people with Alzheimer's disease at the Alzheimer's Association.
Journal reference:
New England Journal of Medicine
Copyright © 2012 HealthDay. All rights reserved.
-
Antipsychotic drugs double risk of death among Alzheimer's patients
Jan 09, 2009 |
not rated yet |
0
-
Drug class not effective for Alzheimer's
Oct 12, 2006 |
not rated yet |
0
-
Specific antipsychotic drugs increase risk of death in elderly dementia patients
Feb 23, 2012 |
not rated yet |
0
-
Studies look at how genes affect antipsychotic drug response
Nov 09, 2006 |
not rated yet |
0
-
Alzheimer's drug fails to reduce significant agitation
May 02, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
question on coriolis effect with drag force
52 minutes ago
-
Question of reflection and transmission of TEM wave in normal incidenc
6 hours ago
-
the rudyak-krasnolutski effective potencial
7 hours ago
-
Normal force for a lever model
8 hours ago
-
gravity is std. therefore can we rate a 'mass at height' by watts?
13 hours ago
-
Calculating on-axis elements of a solenoid
May 22, 2013
- More from Physics Forums - Classical Physics
More news stories
Scientists discover cinnamon compounds' potential ability to prevent Alzheimer's
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia
7 hours ago |
5 / 5 (4) |
0
|
Drug reverses Alzheimer's disease deficits in mice, research confirms
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia
9 hours ago |
not rated yet |
0
|
Multiple research teams unable to confirm high-profile Alzheimer's study
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia
9 hours ago |
5 / 5 (1) |
2
|
Major human drug trial underway for Alzheimer's
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
Alzheimer's disease & dementia
12 hours ago |
not rated yet |
0
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia
May 21, 2013 |
5 / 5 (7) |
0
|
Controlling mood through the motions of mitochondria
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
Motion quotient: IQ predicted by ability to filter motion (w/ video)
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
Scientists discover molecule triggers sensation of itch
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
Researchers find common childhood asthma unconnected to allergens or inflammation
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
Diabetes' genetic underpinnings can vary based on ethnic background, studies say
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Study reveals new mechanism for estrogen suppression of liver lipid synthesis
By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.
Oct 19, 2012
Rank: not rated yet
Remember-Zyprexa Diabetes connection conflict of interest.
Eli Lilly made $67 billion to date,paid $1.4 billion in criminal fines.
Thousands got diabetes as Zyprexa side effect and have to take Lilly insulin to treat the diabetes that was caused by their Zyprexa.
Eli Lilly Zyprexa can ruin your Pancreas and make you a type 2 diabetic in just a few months of use.I took it 1996-2000 and now am a diabetic for it.
'Atypical' antipsychotic Zyprexa is the worst offender of them all.Google-Haszard Zyprexa - got a page up.
-Daniel Haszard